Sevimli, ReşitKaraman, Serdar2024-08-042024-08-0420222147-0634https://doi.org/10.5455/medscience.2021.09.297https://search.trdizin.gov.tr/yayin/detay/522754https://hdl.handle.net/11616/89664In this study, we aimed to compare the functional outcomes and survival of 38 patients with primary bone and metastatic bone tumors who were reconstructed with endoprosthesis. Thirty-eight patients who underwent endoprosthesis for malign bone tumors 2012- 2015 were included in the study. We retrospectively reviewed 38 patients, eight of whom underwent limb salvage with tumor resection prosthesis of tibia, 21 femur, and 9 humerus. When comparing functional outcomes, the revised Musculoskeletal Tumor Society (MSTS) scoring system was used for all surviving patients. The patients were evaluated in two groups as primary bone tumor and metastatic bone tumor. The mean follow-up period of 32 healthy and alive patients was 38 (12 to 98) months. While 12 patients were primary malign bone tumors, the other 26 patients had bone metastasis. All six patients who died during follow-up had a diagnosis of metastatic bone tumor. Periprosthetic infection was observed in two patients, recurrence tumor in one and prosthetic dislocation in one. It was found that the MSTS score in patients with primary bone tumors (22, 6) was statistically significantly higher than in patients with metastases (17, 6) (p<0.05). The score of the patients who had upper extremity (%22) reconstruction was found to be significantly higher than the lower extremity (%78) (p<0.05). It was determined that better functional results were obtained for patients with primary bone tumors than patients with bone metastasis. The low complication rates obtained because of this study, which had an average follow-up of 38 months, showed us that reconstruction with endoprosthesis is promising for tumors of the femur, tibia and humerus.eninfo:eu-repo/semantics/openAccessArticle11119920310.5455/medscience.2021.09.297522754